Implantable central venous access device procedures in haemophilia patients without an inhibitor: Systematic review of the literature and institutional experience

Haemophilia

Volumn 14, Issue 2, 2008, Pages 260-270

  Neunert, Cindy E ^a   Miller, K L ^a   Journeycake, J M ^a   Buchanan, G R ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Central venous access devices; Haemophilia; Surgery

Indexed keywords

BLOOD CLOTTING FACTOR 8; RECOMBINANT BLOOD CLOTTING FACTOR 9;

BOLUS INJECTION; CENTRAL VENOUS CATHETERIZATION; CLINICAL EFFECTIVENESS; COCHRANE LIBRARY; DEVICE INFECTION; HEMATOMA; HEMOPHILIA; HEMOPHILIA A; HEMOPHILIA B; HUMAN; INJURY; MEDLINE; PATIENT SAFETY; POSTOPERATIVE COMPLICATION; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; THROMBOSIS; VASCULAR ACCESS DEVICE;

EID: 40449128860     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2007.01605.x     Document Type: Review

References (157)

1. 1 Liesner RJ, Vora AJ, Hann IM et al. Use of central venous catheters in children with severe congenital coagulopathy. Br J Haematol 1995 ; 91: 203–7.
2. 2 Valentino LA, Ewenstein B, Navickis RJ et al. Central venous access devices in haemophilia. Haemophilia 2004 ; 10: 134–46.
3. 3 Ewenstein BM, Valentino LA, Journeycake JM et al. Consensus recommendations for use of central venous access devices in haemophilia. Haemophilia 2004 ; 10: 629–48.
4. 4 Baudo F, Redaelli R, Caimi TM et al. The continuous infusion of recombinant activated factor VIIa (rFVIIa) in patients with factor VIII inhibitors activates the coagulation and fibrinolytic systems without clinical complications. Thromb Res 2000 ; 99: 21–4.
5. 5 Bell BA, Birch K, Glazer S. Experience with recombinant factor VIIA in an infant hemophiliac with inhibitors to FVIII:C undergoing emergency central line placement. A case report. Am J Pediatr Hematol Oncol 1993 ; 15: 77–9.
6. 6 Carcao MD, Connolly BL, Chait P et al. Central venous catheter‐related thrombosis presenting as superior vena cava syndrome in a haemophilic patient with inhibitors. Haemophilia 2003 ; 9: 578–83.
7. 7 DiMichele DM, Kroner BL. The North American Immune Tolerance Registry: practices, outcomes, outcome predictors. Thromb Haemost 2002 ; 87: 52–7.
8. 8 Lilleyman JS. Domiciliary desensitization therapy for young boys with haemophilia and factor VIII inhibitors. Br J Haematol 1994 ; 86: 433–5.
9. 9 Montoro JB, Altisent C, Pico M et al. Recombinant factor VIIa in continuous infusion during central line insertion in a child with factor VIII high‐titre inhibitor. Haemophilia 1998 ; 4: 762–5.
10. 10 Morado M, Jimenez‐Yuste V, Villar A et al. Complications of central venous catheters in patients with haemophilia and inhibitors. Haemophilia 2001 ; 7: 551–6.
11. 11 Quintana‐Molina M, Martinez‐Bahamonde F, Gonzalez‐Garcia E et al. Surgery in haemophilic patients with inhibitor: 20 years of experience. Haemophilia 2004 ; 10 (Suppl. 2): 30–40.
12. 12 Smith OP, Hann IM. rVIIa therapy to secure haemostasis during central line insertion in children with high‐responding FVIII inhibitors. Br J Haematol 1996 ; 92: 1002–4.
13. 13 Joshi R, Barrett AJ, Wastell C et al. Use of a Hickman catheter for permanent venous access in a patient with severe haemophilia. Clin Lab Haematol 1982 ; 4: 319–21.
14. 14 Rodriguez‐Merchan EC, Rocino A. Literature review of surgery management in inhibitor patients. Haemophilia 2004 ; 10 (Suppl. 2): 22–9.
15. 15 Soto I, Vicente JM, Corte JR et al. Successful induction of immune tolerance with FIX recombinant in a patient with haemophilia B with inhibitor. Haemophilia 2004 ; 10: 401–4.
16. 16 Island ER, Church JA, Shaul DB. Short‐term complications of central line placement in children with the human immunodeficiency virus. J Pediatr Surg 2001 ; 36: 1777–80.
17. 17 Greene WB, DeGnore LT, White GC. Orthopaedic procedures and prognosis in hemophilic patients who are seropositive for human immunodeficiency virus. J Bone Joint Surg Am 1990 ; 72: 2–11.
18. 18 Matsuyama K, Ushijima K, Kano T et al. [Intraoperative use of plasma‐derived activated factor VII (F VII a) in a hemophilia A patient with inhibitors]. Masui 1996 ; 45: 235–8.
19. 19 Hack G, Hofmann P, Brackmann H et al. Regional anaesthesia in hemophiliacs. Anasth Intensivther Notfallmed 1980 ; 15: 45–51.
20. 20 Bonnichon P, Cerceau R. [Indications for long term intravenous devices]. Soins 2001 ; 660: 34–5.
21. 21 Sukhovii M, Nesterov O, Ostrerov S. Long‐term catheterization of the subclavian vein in hemophilia. Klin Khir 1988 ; 3: 74–5.
22. 22 Schimpf K. The role of self‐infusion treatment for the patient with haemophilia. Blut 1978 ; 36: 63–71.
23. 23 Parmar N, Berry LR, Paredes N et al. Effect of heparins on thrombin generation in hemophilic plasma supplemented with FVIII, FVIIa, or FEIBA. Clin Lab 2005 ; 51: 157–66.
24. 24 Bisset RA, Gupta SC, Zammit‐Maempel I. Radiographic and ultrasound appearances of an intra‐mural haematoma of the pylorus. Clin Radiol 1988 ; 39: 316–8.
25. 25 Mauro MA, Vincent LM, Mandell VS et al. Gas within hemophiliac pelvic pseudotumors: CT demonstration. J Comput Assist Tomogr 1984 ; 8: 473–5.
26. 26 Weiss HJ, Turitto VT, Baumgartner HR. Effect of shear rate on platelet interaction with subendothelium in citrated and native blood. I. Shear rate‐dependent decrease of adhesion in von Willebrand’s disease and the Bernard–Soulier syndrome. J Lab Clin Med 1978 ; 92: 750–64.
27. 27 Bajo MA, Del Peso G, Jimenez V et al. Peritoneal dialysis is the therapy of choice for end‐stage renal disease patients with hereditary clotting disorders. Adv Perit Dial 2000 ; 16: 170–3.
28. 28 Blanchette VS, Al‐Musa A, Stain AM et al. Central venous access devices in children with hemophilia: an update. Blood Coagul Fibrinolysis 1997 ; 8 (Suppl. 1): S11–4.
29. 29 Santagostino E, Gringeri A, Muca‐Perja M et al. Study on long‐term safety of Port‐a‐Cath use in children with haemophilia: which alternatives? Haemophilia 2000 ; 6: 277.
30. 30 Tarantino MD, Lail A, Donfield SM et al. Surveillance of infectious complications associated with central venous access devices in children with haemophilia. Haemophilia 2003 ; 9: 588–92.
31. 31 Liesner RJ, Khair K, Hann IM. The impact of prophylactic treatment on children with severe haemophilia. Br J Haematol 1996 ; 92: 973–8.
32. 32 Scribner BH. Letter: Management of hemophilia with atrial catheter. N Engl J Med 1976 ; 295: 233.
33. 33 Yee TT, Beeton K, Griffioen A et al. Experience of prophylaxis treatment in children with severe haemophilia. Haemophilia 2002 ; 8: 76–82.
34. 34 Giangrande PL. Adverse events in the prophylaxis of haemophilia. Haemophilia 2003 ; 9 (Suppl. 1): 50–4 ; discussion 55–6.
35. 35 Nowak‐Gottl U, Escuriola C, Kurnik K et al. Haemophilia and thrombophilia. What do we learn about combined inheritance of both genetic variations? Hamostaseologie 2003 ; 23: 36–40.
36. 36 Ettingshausen CE, Kurnik K, Schobess R et al. Catheter‐related thrombosis in children with hemophilia A: evidence of a multifactorial disease. Blood 2002 ; 99: 1499–500.
37. 37 Babu R, Spicer RD. Implanted vascular access devices (ports) in children: complications and their prevention. Pediatr Surg Int 2002 ; 18: 50–3.
38. 38 Blanchette VS, Manco‐Johnson M, Santagostino E et al. Optimizing factor prophylaxis for the haemophilia population: where do we stand? Haemophilia 2004 ; 4: 97–104.
39. 39 Blanchette VS, McCready M, Achonu C et al. A survey of factor prophylaxis in boys with haemophilia followed in North American haemophilia treatment centres. Haemophilia 2003 ; 9 (Suppl. 1): 19–26 ; discussion 26.
40. 40 Chambost H, Ljung R. Changing pattern of care of boys with haemophilia in western European centres. Haemophilia 2005 ; 11: 92–9.
41. 41 Collins PW, Khair KS, Liesner R et al. Complications experienced with central venous catheters in children with congenital bleeding disorders. Br J Haematol 1997 ; 99: 206–8.
42. 42 Domm JA, Hudson MG, Janco RL. Complications of central venous access devices in paediatric haemophilia patients. Haemophilia 2003 ; 9: 50–6.
43. 43 Fontes B, Ferreira Filho AA, Carelli CR et al. Percutaneous catheterization of the subclavian vein in hemophiliac patients: report of 47 cases. Int Surg 1992 ; 77: 118–21.
44. 44 Hothi DK, Kelsall W, Baglin T et al. Bacterial endocarditis in a child with haemophilia B: risks of central venous catheters. Haemophilia 2001 ; 7: 507–10.
45. 45 Li CH, Ou Y, Lee AC et al. Septic arthritis in hemophilia with central venous catheter: a case report. Pediatr Hematol Oncol 2000 ; 17: 187–9.
46. 46 Lindley C, Sawyer W, Haddon T et al. Comparison of PT, aPTT, and factor VII values obtained by concurrent sample collection by direct venipuncture and peripheral venous catheters. Pharmacotherapy 1994 ; 14: 224–8.
47. 47 Ljung R. Central venous catheters in children with haemophilia. Blood Rev 2004 ; 18: 93–100.
48. 48 Ljung R. Central venous lines in haemophilia. Haemophilia 2003 ; 9 (Suppl. 1): 88–92 ; discussion 93.
49. 49 Ljung R. Second Workshop of the European Paediatric Network for Haemophilia Management, 17–19 September 1998 in Vitznau/Switzerland. Haemophilia 1999 ; 5: 286–91.
50. 50 Ljung R, Van Den Berg M, Petrini P et al. Port‐A‐Cath usage in children with haemophilia: experience of 53 cases. Acta Paediatr 1998 ; 87: 1051–4.
51. 51 Manco‐Johnson M. Hemophilia management: optimizing treatment based on patient needs. Curr Opin Pediatr 2005 ; 17: 3–6.
52. 52 McWhirter WR, Gray L. Indwelling intravenous catheter in a young haemophiliac. Lancet 1988 ; 2: 99–100.
53. 53 Miser AW, Roach JE, Harmel RP Jr et al. Insertion of a central venous catheter for long‐term venous access in a child with severe hemophilia and recurrent intracranial hemorrhage. Clin Pediatr (Phila) 1984 ; 23: 589.
54. 54 Perkins JL, Johnson VA, Osip JM et al. The use of implantable venous access devices (IVADs) in children with hemophilia. J Pediatr Hematol Oncol 1997 ; 19: 339–44.
55. 55 Shapiro AD. Why is primary prophylaxis underutilized in the United States? Haemophilia 2003 ; 9: 670–2.
56. 56 Srivaths PR, Rozans MK, Kelly E Jr et al. Bacillus cereus central line infection in an immunocompetent child with hemophilia. J Pediatr Hematol Oncol 2004 ; 26: 194–6.
57. 57 Valentino LA, Kapoor M. Central venous access devices in patients with hemophilia. Expert Rev Med Devices 2005 ; 2: 699–711.
58. 58 Vidler V, Richards M, Vora A. Central venous catheter‐associated thrombosis in severe haemophilia. Br J Haematol 1999 ; 104: 461–4.
59. 59 Vidler V. Use of Port‐a‐Caths in the management of paediatric haemophilia. Prof Nurse 1994 ; 10: 48–50.
60. 60 Wesenberg F, Flaatten H, Janssen CW Jr. Central venous catheter with subcutaneous injection port (Port‐A‐Cath): 8 years clinical follow up with children. Pediatr Hematol Oncol 1993 ; 10: 233–9.
61. 61 Geraghty S, Kleinert D. Additional data on the morbidity of central venous access devices in patients with haemophilia. Haemophilia 1998 ; 4: 66.
62. 62 Berntorp E. The treatment of haemophilia, including prophylaxis, constant infusion and DDAVP. Baillieres Clin Haematol 1996 ; 9: 259–71.
63. 63 Panicker J, Warrier I, Thomas R et al. The overall effectiveness of prophylaxis in severe haemophilia. Haemophilia 2003 ; 9: 272–8.
64. 64 Dargaud Y, Meunier S, Negrier C. Haemophilia and thrombophilia: an unexpected association! Haemophilia 2004 ; 10: 319–26.
65. 65 Franchini M. Thrombotic complications in patients with hereditary bleeding disorders. Thromb Haemost 2004 ; 92: 298–304.
66. 66 Journeycake JM, Quinn CT, Miller KL et al. Catheter‐related deep venous thrombosis in children with hemophilia. Blood 2001 ; 98: 1727–31.
67. 67 Kenney BD, David M, Bensoussan AL. Anticoagulation without catheter removal in children with catheter‐related central vein thrombosis. J Pediatr Surg 1996 ; 31: 816–8.
68. 68 Medeiros D, Miller KL, Rollins NK et al. Contrast venography in young haemophiliacs with implantable central venous access devices. Haemophilia 1998 ; 4: 10–5.
69. 69 Price VE, Carcao M, Connolly B et al. A prospective, longitudinal study of central venous catheter‐related deep venous thrombosis in boys with hemophilia. J Thromb Haemost 2004 ; 2: 737–42.
70. 70 Blanchette VS, Al‐Musa A, Stain AM et al. Central venous access catheters in children with haemophilia. Blood Coagul Fibrinolysis 1996 ; 7 (Suppl. 1): S39–44.
71. 71 Bollard CM, Teague LR, Berry EW et al. The use of central venous catheters (portacaths) in children with haemophilia. Haemophilia 2000 ; 6: 66–70.
72. 72 Girvan DP, DeVeber LL, Inwood MJ et al. Subcutaneous infusion ports in the pediatric patient with hemophilia. J Pediatr Surg 1994 ; 29: 1220–3.
73. 73 Ljung R, Petrini P, Lindgren AK et al. Implantable central venous catheter facilitates prophylactic treatment in children with haemophilia. Acta Paediatr 1992 ; 81: 918–20.
74. 74 Miller K, Buchanan GR, Zappa S et al. Implantable venous access devices in children with hemophilia: a report of low infection rates. J Pediatr 1998 ; 132: 934–8.
75. 75 Santagostino E, Gringeri A, Muca‐Perja M et al. A prospective clinical trial of implantable central venous access in children with haemophilia. Br J Haematol 1998 ; 102: 1224–8.
76. 76 Van Den Berg HM, Fischer K, Roosendaal G et al. The use of the Port‐A‐Cath in children with haemophilia–a review. Haemophilia 1998 ; 4: 418–20.
77. 77 Schultz WH, Ware R, Filston HC et al. Prolonged use of an implantable central venous access system in a child with severe hemophilia. J Pediatr 1989 ; 114: 100–1.
78. 78 Teitel JM, Barnard D, Israels S et al. Home management of haemophilia. Haemophilia 2004 ; 10: 118–33.
79. 79 Hilgartner M, Kleinert D. Morbidity of central lines in patients with coagulation deficiencies. Pediatr Res 1995 ; 37: 158A.
80. 80 Hay CR. Hemophilia treatment. Immune tolerance induction: prospective clinical trials. Haematologica 2000 ; 85: 52–5 ; discussion 55–6.
81. 81 Martinowitz U, Schulman S, Gitel S et al. Adjusted dose continuous infusion of factor VIII in patients with haemophilia A. Br J Haematol 1992 ; 82: 729–34.
82. 82 Warrier I, Baird‐Cox K, Cygan ML et al. Experience with central venous catheters in children with hemophilia. Thromb Haemost 1993 ; 69: 854.
83. 83 Powell T, Blumoff R, Mandel S. Vascular access in hemophilia. Am Surg 1981 ; 47: 408–9.
84. 84 Ries C, Perkins HA. Saphenous vein arteriovenous fistula. JAMA 1973 ; 226: 665–6.
85. 85 Sussman L, Lozman H. Arteriovenous fistula for self treatment of hemophilia. JAMA 1974 ; 230: 437–8.
86. 86 West N, Sells R, Korn Y et al. A new modified bovine heterograft for vascular access in hemophiliacs. Clin Lab Haematol 1984 ; 6: 375–7.
87. 87 Kasper C. Treatment of factor VIII inhibitors. Prog Clin Biol Res 1989 ; 9: 57–86.
88. 88 Brackmann HH, Oldenburg J, Schwaab R. Immune tolerance for the treatment of factor VIII inhibitors–twenty years’‘Bonn protocol’. Vox Sang 1996 ; 70 (Suppl. 1): 30–5.
89. 89 Carlborg E, Astermark J, Lethagen S et al. The Malmo model for immune tolerance induction: impact of previous treatment on outcome. Haemophilia 2000 ; 6: 639–42.
90. 90 Wight J, Paisley S, Knight C. Immune tolerance induction in patients with haemophilia A with inhibitors: a systematic review. Haemophilia 2003 ; 9: 436–63.
91. 91 Brackmann HH. Induced immune tolerance in factor VIII inhibitor patients. Prog Clin Biol Res 1986 ; 150: 181–95.
92. 92 Damiano ML, Hutter JJ Jr. Immune tolerance for haemophilia patients with inhibitors: analysis of the western United States experience. The Tri‐Regional Nursing Group. Haemophilia 2000 ; 6: 526–32.
93. 93 Feldman B, Rivard G, Isreals S et al. Preliminary results from the Canadian Hemophilia Prophylaxis Trial. Haemophilia 2000 ; 6: 272.
94. 94 Nilsson IM, Berntorp E, Zettervall O. Induction of immune tolerance in patients with hemophilia and antibodies to factor VIII by combined treatment with intravenous IgG, cyclophosphamide, and factor VIII. N Engl J Med 1988 ; 318: 947–50.
95. 95 Blatt P, White GC, McMillan CW et al. Treatment of anti‐factor VIII antibodies. Thromb Haemost 1977 ; 38: 514–23.
96. 96 Blanchette VS, Al‐Trabolsi H, Stain AM. High risk of central venous line‐associated thrombosis in boys with hemophilia. Blood 1999 ; 94: 234a.
97. 97 Brown S, Aledort LM, Lee CA et al. Optimal treatment of regimens for patients with bleeding disorders. Haemophilia 2001 ; 7: 313–20.
98. 98 Geraghty S, Kleinert D. Use and morbidity of venous access devices in patients with hemophilia. J Intraven Nurs 1998 ; 21: 70–5.
99. 99 Girisch M, Rauch R, Lischetzki G et al. Central venous catheters (Port‐A‐Cath) for treatment of children with haemophilia. Haemophilia 2002 ; 8: 488.
100. 100 Goldsmith J, Miller R, Boody B et al. Central venous catheter related complications in children with hemophilia. Blood 1995 ; 86: 872a.
101. 101 Harrington C, Pollard D, Yee TT et al. Experience of home treatment training for children with severe hemophilia and their parents. Haemophilia 2000 ; 6: 274.
102. 102 Hathaway W, Christian MJ, Clarke SL et al. Comparison of continuous and intermittent factor VIII concentrate therapy in hemophilia A. Am J Hematol 1984 ; 17: 85–8.
103. 103 Inwood M. Aids for children on self infusion program. J Pediatr 1978 ; 92: 78–9.
104. 104 Journeycake J, Buchanan GR. Catheter‐related thrombosis in children with hemophilia A. Blood 2002 ; 99: 1500.
105. 105 Ljung R, Lindergren AC, Tengborn L et al. The feasibility of long‐term venous access in children with hemophilia. Semin Hematol 1994 ; 31 (Suppl. 2): 16–8.
106. 106 McMahon C, Smtih J, Lakshmandass G et al. Right atrial catheters, the way forward to facilitate successful prophylactic treatment regimens in severe hemophilia. Haemophilia 1998 ; 4: 171.
107. 107 Ragni M, Hord JD, Blatt J. Central venous catheter infections in hemophiliacs undergoing prophylaxis or immune tolerance with clotting factor concentrate. Haemophilia 1997 ; 3: 90–5.
108. 108 Ragni MV. Infectious and thrombotic complication of central venous catheters in patients with hemophilia. Clin Infect Dis 1998 ; 5: 19–22.
109. 109 Ross‐Degnan D, Soumeri SB, Avorn J et al. Hemophilia home treatment. Int J Technol Assess Health Care 1995 ; 11: 327–44.
110. 110 Rothschild C, Merckx J, Clairicia M et al. Experience with implantable venous access devices in haemophilic children treated intensively: a low rate of complications. Haemophilia 2000 ; 6: 276.
111. 111 Stevens M. Using subcutaneous implanted ports in hemophiliacs. Transfusion 1994 ; 34: 733.
112. 112 Tusell J, Cid AR, Sosa R et al. Haemophilia prophylactic treatment in Spain. Haemophilia 2002 ; 8: 729–30.
113. 113 Tusell J, Villar A, Lopez‐Fernandez et al. Ports in children with congenital coagulopathies: Spanish registry. Haemophilia 2002 ; 8: 488.
114. 114 Yee T, Beeton K, Harrington C et al. Experience of prophylaxis treatment in children with severe hemophilia. Haemophilia 2000 ; 6: 278.
115. 115 Levine P. Efficacy of self therapy in hemophilia: a study of 72 patients with hemophilia. N Engl J Med 1974 ; 291: 1381–4.
116. 116 Bona R, Weinstein RA, Weisman SJ et al. The use of continuous factor concentrates in the treatment of hemophilia. Am J Pediatr Hematol Oncol 1989 ; 32: 8–13.
117. 117 Aledort L. Prophylaxis: the next hemophilia treatment. J Intern Med 1992 ; 232: 1–2.
118. 118 McMillan C, Webster WP, Roberts HR et al. Continuous infusion of factor VIII in classic hemophilia. Br J Haematol 1970 ; 18: 659–67.
119. 119 Weinstein R, Bona RD, Rickles FR. Continuous infusion of monoclonal anti‐body purified factor VIII. Am J Hematol 1991 ; 36: 211–2.
120. 120 Osip J, Heisel M, Johnson V et al. Implantable venous access device in persons with bleeding disorders: a follow‐up of complications. Haemophilia 1998 ; 4: 171.
121. 121 Petrini P, Lindvall N, Egberg N et al. Prophylaxis with factor concentrates in preventing hemophilic arthropathy. Am J Pediatr Hematol Oncol 1991 ; 13: 280–97.
122. 122 Manco‐Johnson MJ, Nuss R, Geraghty S et al. Results of secondary prophylaxis in children with severe hemophilia. Am J Hematol 1994 ; 47: 113–7.
123. 123 Nilsson IM, Berntorp E, Lofqvist T et al. Twenty‐five years’ experience of prophylactic treatment in severe haemophilia A and B. J Intern Med 1992 ; 232: 25–32.
124. 124 Buchanan GR, Miller KL, Zajac JL. Upper venous system thrombosis in haemophilia patients with long‐term implantable central venous catheters. Hemophilia 2000 ; 6: 271.
125. 125 Harvey MP, Trent RJ, Joshua DE et al. Complications associated with indwelling venous Hickman catheters in patients with hematological disorders. Aust NZ J Med 1986 ; 16: 211–5.
126. 126 Ingram J, Weitzman S, Greenberg M et al. Complications of indwelling venous access lines in the pediatric hematology patient: a prospective comparison of external venous catheters versus subcutaneous ports. Am J Pediatr Hematol Oncol 1991 ; 13: 130–6.
127. 127 Kappers‐Klunne M, Degener JE, Stijnen T et al. Complications from long term indwelling central venous catheter in hematological patients with special reference to infection. Cancer 1989 ; 64: 1747–52.
128. 128 Shapiro A, Donfield SM. Complications of central venous access devices (CVAD) in children with haemophilia. Haemophilia 2000 ; 6: 278.
129. 129 La Quaglia M, Lucas A, Thaler HT et al. A prospective analysis of vascular access device‐related infections in children. J Paediatr Surg 1992 ; 27: 840–2.
130. 130 Mumtaz H, Williams V, Hauer‐Jensen M et al. Central venous catheter placement in patients with disorders of haemostasis. Am J Surg 2001 ; 180: 503–6.
131. 131 Johnson E, Finan P, Parapia L. Long‐term venous access in severe haemophiliac. Br J Parental Ther 1986 ; 7: 47.
132. 132 Hockenberry MJ, Schultz WH, Bryant R. Experience with minimal complications in implanted catheters in children. J Pediatr Hematol Oncol 1989 ; 11: 295–9.
133. 133 McMahon C, Smith J, Khair K et al. Central venous access devices in children with congenital coagulation disorders: complications and long‐term outcome. Br J Haematol 2000 ; 110: 461–8.
134. 134 Vora A, Lilleyman JS. Vascular access in young hemophiliacs: use of indwelling central venous catheters. Int J Pediatr Hematol Oncol 1994 ; 1: 521–7.
135. 135 Warrier I, Baird‐Cox K, Lusher JM. Use of central venous catheters in children with haemophilia: one haemophilia treatment centre experience. Haemophilia 1997 ; 3: 194–8.
136. 136 Zappa SC, Johnson AG, Cochran CJ et al. Implantable intravenous access devices in children with hemophilia. Arch Pediatr Adolesc Med 1994 ; 148: 327–30.
137. 137 Van Den Berg HM, Fischer K, Mauser‐Bunschoten EP et al. Long‐term outcome of individualized prophylactic treatment of children with severe haemophilia. Br J Haematol 2001 ; 112: 561–5.
138. 138 Manco‐Johnson MJ, Nuss R, Abshire T et al. Port infections in children with haemophilia. Haemophilia 2000 ; 6: 275.
139. 139 Ljung R, Aronis‐Vournas S, Kurnik‐Auberger K et al. Treatment of children with haemophilia in Europe: a survey of 20 centres in 16 countries. Haemophilia 2000 ; 6: 619–24.
140. 140 Abildgaard C. Progress and problems in hemophilia and von Willebrand disease. Adv Pediatr 1984 ; 31: 137–77.
141. 141 Gringeri A, Bianchi A, Group ES. Evaluation study on prophylaxis: a randomized Italian trial (ESPRIT): two‐year report. Thromb Haemost 1999 ; 8 (Suppl. 1): 1487.
142. 142 Levin J, Ness PM, Bell WR. Continuous infusion of factor VIII concentrate for therapy of hemophilia A. Blood 1981 ; 58: 220a.
143. 143 Liesner R. Prophylaxis in haemophilic children. Blood Coagul Fibrinolysis 1997 ; 8: s7–10.
144. 144 Ljung R, Van Den Berg M, Petrini P et al. Experience with the Port‐A‐Cath in children with haemophilia: a multicentre study. Haemophilia 1996 ; 2 (Suppl. 1): 17.
145. 145 Lucia J, Aznar JA, Sosa R et al. Haemophilia prophylactic treatment in Spain. Haemophilia 2002 ; 8: 489.
146. 146 Manco‐Johnson MJ, Nuss R, Geraghty S et al. A prophylactic program in the United States: experience and issues. Semin Hematol 1994 ; 31: 10–2.
147. 147 Mannucci P, Mendolicchio L, Gringeri A. Use of prophylaxis to prevent complications of hemophilia. Adv Exp Med Biol 2001 ; 489: 59–64.
148. 148 Morado M, Villar A, Jimenez Yuste V et al. Complications of central venous catheters in patients with haemophilia and inhibitors. Haemophilia 2000 ; 6: 275–6.
149. 149 Nilsson IM, Berntorp E, Lofqvist T. Prophylactic treatment of haemophilia in Sweden. Hemost Thromb 1991 ; 65: 822.
150. 150 Panicker J, Warrier I, Lusher J. The impact of prophylaxis on children with severe haemophilia. Haemophilia 2002 ; 8: 489–90.
151. 151 Panicker J, Warrier I, Lusher JM, Thomas R. The impact of prophylaxis on children with severe hemophilia. Blood 2001 ; 98: 531a.
152. 152 Petrini P, Klementz G. Clinical experience of early prophylaxis in young haemophiliacs. Haemophilia 1996 ; 2 (Suppl. 1): 63.
153. 153 Van Den Berg HM, Fischer K, Van Der Bom JG et al. Effects of prophylactic treatment regimens in children with severe haemophilia: a comparison of different strategies. Haemophilia 2002 ; 8: 43–6.
154. 154 Van Dijk K, Van Den Berg M, Van Der Bom JG. Complications of port‐a‐cath (PAC) in children with haemophilia. Haemophilia 2002 ; 2: 737–42.
155. 155 Crary SE, Buchanan GR, Journeycake JM. Fatal central venous catheter‐related infection in haemophilia. Haemophilia 2006 ; 12: 183–6.
156. 156 Kasper CK, Boylen AL, Ewing NP et al. Hematologic management of hemophilia A for surgery. JAMA 1985 ; 253: 1279–83.
157. 157 Journeycake JM, Brambilla D, Ragni MV. Central venous access device‐related infections in hemophilia. ASH Annu Meet Abstr 2005 ; 106: 3216.